These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. A region of N-type Ca(2+) channel critical for blockade by the dihydropyridine amlodipine. Miyashita Y; Furukawa T; Kamegaya E; Yoshii M; Nukada T Eur J Pharmacol; 2010 Apr; 632(1-3):14-22. PubMed ID: 20097194 [TBL] [Abstract][Full Text] [Related]
5. Distinctions in the molecular determinants of charged and neutral dihydropyridine block of L-type calcium channels. Lacinová L; An RH; Xia J; Ito H; Klugbauer N; Triggle D; Hofmann F; Kass RS J Pharmacol Exp Ther; 1999 Jun; 289(3):1472-9. PubMed ID: 10336541 [TBL] [Abstract][Full Text] [Related]
6. Distinct properties of amlodipine and nicardipine block of the voltage-dependent Ca2+ channels Cav1.2 and Cav2.1 and the mutant channels Cav1.2/dihydropyridine insensitive and Cav2.1/dihydropyridine sensitive. Lin M; Aladejebi O; Hockerman GH Eur J Pharmacol; 2011 Nov; 670(1):105-13. PubMed ID: 21910984 [TBL] [Abstract][Full Text] [Related]
7. Five different profiles of dihydropyridines in blocking T-type Ca(2+) channel subtypes (Ca(v)3.1 (alpha(1G)), Ca(v)3.2 (alpha(1H)), and Ca(v)3.3 (alpha(1I))) expressed in Xenopus oocytes. Furukawa T; Nukada T; Namiki Y; Miyashita Y; Hatsuno K; Ueno Y; Yamakawa T; Isshiki T Eur J Pharmacol; 2009 Jun; 613(1-3):100-7. PubMed ID: 19401195 [TBL] [Abstract][Full Text] [Related]
8. Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. Furukawa T; Yamakawa T; Midera T; Sagawa T; Mori Y; Nukada T J Pharmacol Exp Ther; 1999 Nov; 291(2):464-73. PubMed ID: 10525060 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of type A GABA receptors by L-type calcium channel blockers. Das P; Bell-Horner CL; Huang RQ; Raut A; Gonzales EB; Chen ZL; Covey DF; Dillon GH Neuroscience; 2004; 124(1):195-206. PubMed ID: 14960351 [TBL] [Abstract][Full Text] [Related]
10. A genetic screen for dihydropyridine (DHP)-resistant worms reveals new residues required for DHP-blockage of mammalian calcium channels. Kwok TC; Hui K; Kostelecki W; Ricker N; Selman G; Feng ZP; Roy PJ PLoS Genet; 2008 May; 4(5):e1000067. PubMed ID: 18464914 [TBL] [Abstract][Full Text] [Related]
11. Serine residue in the IIIS5-S6 linker of the L-type Ca2+ channel alpha 1C subunit is the critical determinant of the action of dihydropyridine Ca2+ channel agonists. Yamaguchi S; Okamura Y; Nagao T; Adachi-Akahane S J Biol Chem; 2000 Dec; 275(52):41504-11. PubMed ID: 11022040 [TBL] [Abstract][Full Text] [Related]
12. Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Peterson BZ; Catterall WA Mol Pharmacol; 2006 Aug; 70(2):667-75. PubMed ID: 16675661 [TBL] [Abstract][Full Text] [Related]
14. Molecular determinants of diltiazem block in domains IIIS6 and IVS6 of L-type Ca(2+) channels. Hockerman GH; Dilmac N; Scheuer T; Catterall WA Mol Pharmacol; 2000 Dec; 58(6):1264-70. PubMed ID: 11093762 [TBL] [Abstract][Full Text] [Related]
15. Molecular determinants of frequency dependence and Ca2+ potentiation of verapamil block in the pore region of Cav1.2. Dilmac N; Hilliard N; Hockerman GH Mol Pharmacol; 2004 Nov; 66(5):1236-47. PubMed ID: 15286207 [TBL] [Abstract][Full Text] [Related]
16. A small-molecule screen in C. elegans yields a new calcium channel antagonist. Kwok TC; Ricker N; Fraser R; Chan AW; Burns A; Stanley EF; McCourt P; Cutler SR; Roy PJ Nature; 2006 May; 441(7089):91-5. PubMed ID: 16672971 [TBL] [Abstract][Full Text] [Related]
17. Binding mechanism investigations guiding the synthesis of novel condensed 1,4-dihydropyridine derivatives with L-/T-type calcium channel blocking activity. Schaller D; Gündüz MG; Zhang FX; Zamponi GW; Wolber G Eur J Med Chem; 2018 Jul; 155():1-12. PubMed ID: 29843108 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of voltage-gated L-type calcium channels by labedipinedilol-A involves protein kinase C in rat cerebrovascular smooth muscle cells. Wu BN; Chen ML; Dai ZK; Lin YL; Yeh JL; Wu JR; Chen IJ Vascul Pharmacol; 2009; 51(2-3):65-71. PubMed ID: 19298869 [TBL] [Abstract][Full Text] [Related]
19. Molecular requirements for L-type Ca2+ channel blockade by testosterone. Scragg JL; Dallas ML; Peers C Cell Calcium; 2007 Jul; 42(1):11-5. PubMed ID: 17173968 [TBL] [Abstract][Full Text] [Related]
20. Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Thayer SA; Welcome M; Chhabra A; Fairhurst AS Biochem Pharmacol; 1985 Jan; 34(2):175-80. PubMed ID: 2981533 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]